Aspira Women's Health Inc. (AWHL)
Healthcare · OQX · US
Price as at 30 Sept 2026, 16:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Aspira Women's Health Inc. trades at $0.23. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 29 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; and ENDOinform a multi-marker test program that combines serum proteins, proprietary miRNAs, and clinical data (metadata), for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force; Aspira Synergy platform; and with marketing and distribution agreements. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz; and a strategic alliance agreement with Quest Diagnostics Incorporated and The Cleveland Clinic Foundation. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
AWHL passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
AWHL peers
The largest companies in the same industry (Diagnostics & Research), then in the same sector.
- TMO Thermo Fisher Scientific Inc.
- WAT Waters Corporation
- DGX Quest Diagnostics Incorporated
- ICLR ICON Public Limited Company
- CRL Charles River Laboratories International, Inc.
- QIA.DE Qiagen N.V.
- BLLN BillionToOne, Inc.
- SHC Sotera Health Company
Every healthcare company we cover is on the Healthcare hub.
Common questions
Where does SteadyShares get its AWHL data?
Fundamentals for AWHL come from company filings and exchange data, as listed on OQX; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:16 UTC and is delayed. Our data quality score for this company is 63/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AWHL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.